Nā Hopena Hou o ka CD7-Targeted CAR-T Therapy no T-ALL a me T-LBL

Ua hōʻike ʻia kahi hoʻokolohua lapaʻau hou i nā holomua koʻikoʻi i ka mālama ʻana i ka relapsed a refractory T-cell acute lymphoblastic leukemia (T-ALL) a me T-cell lymphoblastic lymphoma (T-LBL) me ka hoʻohana ʻana i ka CD7-targeted chimeric antigen receptor (CAR) T cell therapy. ʻO ke aʻo ʻana, i mālama ʻia e kahi hui mai ka Halemai ʻo Hebei Yanda Lu Daopei a me ka Lu Daopei Institute of Hematology, ua pili i 60 mau maʻi i loaʻa i hoʻokahi mahele o nā cell T anti-CD7 CAR (NS7CAR) i koho kūlohelohe ʻia.

He mea hoʻoikaika nui nā hopena o ka hoʻokolohua. I ka lā 28, ua loaʻa i ka 94.4% o nā maʻi ke kala piha hohonu (CR) i loko o ka iwi iwi. Eia kekahi, ma waena o nā maʻi 32 me ka maʻi extramedullary, ua hōʻike ʻo 78.1% i kahi pane maikaʻi, me 56.3% e loaʻa ana ke kala piha a me 21.9% e loaʻa ana ke kala hapa. ʻO nā helu ola holoʻokoʻa ʻelua makahiki a me ke ola ʻole holomua he 63.5% a me 53.7%, kēlā me kēia.

He mea kaulana kēia lāʻau lapaʻau hou no kona ʻano palekana hiki ke hoʻokele ʻia, me ka cytokine release syndrome e kū nei i 91.7% o nā maʻi (ʻo ka hapa nui he 1/2), a ʻike ʻia ka neurotoxicity i 5% o nā hihia. Eia kekahi, ua ʻike ʻia ka noiʻi ʻana ua ʻoi aku ka kiʻekiʻe o nā helu ola ʻole holomua o nā maʻi i hoʻomau me nā hoʻoili hoʻohui ma hope o ka hoʻokō ʻana i ka CR i hoʻohālikelike ʻia me ka poʻe i hana ʻole.

Ke noiʻi nei kā mākou hui i ka hiki o ka lāʻau lapaʻau CD7 CAR-T cell me kā mākou huahana ponoʻī, me ka manaʻo e kōkua i ka holomua o nā lāʻau lapaʻau no nā maʻi ʻino T-cell.

Hōʻike kēia mau ʻike i ka hiki o ka lāʻau lapaʻau CAR-T cell i hoʻopaʻa ʻia me CD7 e hāʻawi i ka manaʻolana hou no nā poʻe maʻi me ka T-ALL a me T-LBL refractory a i ʻole relapsed, e hōʻailona ana i kahi hanana koʻikoʻi i ke kaua e hoʻomau nei e kūʻē i kēia mau maʻi paʻakikī.